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Abstract
Aims: Enrolling children into several trials could increase recruitment and lead to quicker delivery of optimal care in
paediatric intensive care units (PICU). We evaluated decisions taken by clinicians and parents in PICU on co-enrolment for
two large pragmatic trials: the CATCH trial (CATheters in CHildren) comparing impregnated with standard central venous
catheters (CVCs) for reducing bloodstream infection in PICU and the CHIP trial comparing tight versus standard control of
hyperglycaemia.
Methods: We recorded the period of trial overlap for all PICUs taking part in both CATCH and CHiP and reasons why
clinicians decided to co-enrol children or not into both studies. We examined parental decisions on co-enrolment by
measuring recruitment rates and reasons for declining consent.
Results: Five PICUs recruited for CATCH and CHiP during the same period (an additional four opened CATCH after having
closed CHiP). Of these five, three declined co-enrolment (one of which delayed recruiting elective patients for CATCH whilst
CHiP was running), due to concerns about jeopardising CHiP recruitment, asking too much of parents, overwhelming
amounts of information to explain to parents for two trials and a policy against co-enrolment. Two units co-enrolled in
order to maximise recruitment to both trials. At the first unit, 35 parents were approached for both trials. 17/35 consented
to both; 13/35 consented to one trial only; 5/35 declined both. Consent rates during co-enrolment were 29/35 (82%) and 18/
35 (51%) for CATCH and CHiP respectively compared with 78% and 51% respectively for those approached for a single trial
within this PICU. The second unit did not record data on approaches or refusals, but successfully co-enrolled one child.
Conclusions: Co-enrolment did not appear to jeopardise recruitment or overwhelm parents. Strategies for seeking consent
for multiple trials need to be developed and should include how to combine information for parents and patients.
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Introduction
Rapid changes in practice result in a constant stream of drugs,
procedures and devices that need to be evaluated in critically ill
children. Many treatments and interventions used in paediatric
intensive care (PICU) have no evidence base or are extrapolated
from results of adult studies. For example, up to 90% of drugs
prescribed to children in hospital are unlicensed and have either
not been evaluated at all in children or for the specific condition
for which the drug is used, and 67% of children receive drugs
prescribed in an unlicensed or ‘off-label’ manner [1,2,3,4]. Huge
assumptions are made when drugs established in adult practice are
used in children without supportive paediatric trials [5].
The growing expectation of evidence-based practice has led to
improved infrastructure to support clinical trials in children in the
UK. For example, national audit data collated by the Paediatric
Intensive Care Audit Network (PICANet) can help to define
eligible patient populations when planning multi-centre trials and
assist with data capture [6]. More recently, the NIHR Medicines
for Children Research Network (MCRN) was established to help
increase the evidence base by improving the co-ordination, speed
and quality of randomised controlled trials of medicines for
children and young people by facilitating the acknowledged
bureaucratic burden involved in establishing trials in the UK and
encouraging pharmaceutical investment [7].
As the demand for trials in PICU continues to increase,
concurrent studies need to make room for each other and
minimise the burden of involvement on patients, parents and staff.
At the time of writing, there were 145 studies listed on the UK
Clinical Research Network Study Portfolio (http://public.ukcrn.
org.uk) as actively recruiting children. Large sample sizes are
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required to adequately assess new treatments and interventions
(the two trials included in this study aimed to recruit 1500 and
1200 children each) yet PICU has a finite capacity, with a total of
18,905 admissions nationally in 2010 [8]. Additionally, recruit-
ment in PICU is particularly difficult as parents and children are
already placed in a stressful situation [9].
Enrolling children into several trials at the same time can
potentially make recruitment more efficient [10]. Co-enrolment
has been successful in clinical trials for critically ill children in
Africa and is feasible and acceptable for studies of AIDS
treatments in children [11,12,13,14]. A tri-nation survey found
that 52% of clinicians or research coordinators had enrolled an
ICU patient into more than one ICU study in the past year, and
that respondents working in paediatric compared with adult
critical care were more likely to endorse co-enrolment [15].
However, 13% stated that they would not offer enrolment of a
patient into two randomized trials under any circumstances [15].
The stress researchers feel when recruiting in PICU may be
compounded with more than one trial [16].
Ethics requirements are perceived as a barrier to co-enrolment.
However, there are no explicit ethics committee guidelines that
prohibit or discourage recruitment of children into more than one
trial [17]. The MRC states that participation in more than one
research study might be potentially beneficial both for the children
involved and for the research, as long as the potential benefits and
risks of doing so are carefully explored and clearly understood by
the child and family [18].
No reports have yet been published of the practical issues arising
when PICU clinicians are asked to co-enrol patients into two
randomised controlled trials. We report PICU and parental
decisions about participating in two PICU trials and determine the
impact of co-enrolment on recruitment rates.
Methods
We evaluated co-enrolment for two concurrent trials targeted at
similar populations in PICU:
1. CATCH (CATheters in CHildren HTA project ref 08/13/47
ISRCTN34884569)
2. CHIP (Control of Hyperglycaemia in Paediatric intensive care:
ISRCTN 61735247, http://www.controlled-trials.com)
Although other trials (e.g. SLEEPs, OXIC-2 and THERMIC-2)
were recruiting in PICU at the same time, our study focuses only
on CATCH and CHiP, as these are the largest PICU trials to date
and have a large recruitment overlap.
Ethics statement: Written informed consent was obtained for all
participants in CATCH and CHiP. Co-enrolment was permitted
in both trial protocols. CATCH was approved by the South West
Medical Research Ethics Committee (MREC) on 19/02/2010
(ref: 09/H0206/69). CHiP was approved by Brighton East REC
on 01/06/2007 (ref: 07/Q1907/24).
PICU Decisions
We recorded the period of trial overlap for all PICUs taking
part in both CATCH and CHiP. We examined reasons for PICU
clinicians deciding whether or not to co-enrol children into both
studies.
Parental Decisions
We examined parental decisions on co-enrolment to CATCH
and CHiP by measuring whether being approached for co-
enrolment affected recruitment rates, and collecting any reasons
for refusal to consent. We compared recruitment rates for parents
given the opportunity to co-enrol with consent rates for parents
approached for one trial only. We retrieved data on the number of
children who were eligible, approached and consented and
collected reasons for refusal by parents of children approached
for both trials. The CATCH protocol states that research nurses
should routinely ask for reasons for non-consent but make clear to
the parents/legal guardian that they do not have to provide a
reason unless happy to do so. We also recorded research nurses’
experiences in seeking consent for two concurrent trials.
Consent Process
CATCH is a multicentre 3-arm randomised controlled trial that
aims to determine the effectiveness of heparin coated or antibiotic
impregnated central venous catheters (CVCs) compared with
standard CVCs for preventing hospital acquired blood stream
infection in children admitted to PICU. Children were rando-
mised to either standard, heparin-coated or antibiotic-impregnat-
ed CVCs, all of which are in routine use in PICU. The trial aims
to recruit 1200 children under 16 years of age admitted to one of
the 12 trial PICUs between November 2010 and September 2012.
CHiP is the largest PICU trial completed to date. It aimed to
determine whether strict control of blood glucose using insulin in
children admitted to PICU reduced mortality, morbidity and/or
the use of healthcare resources compared with standard practices.
Children were randomised to receive either standard care or tight
glycaemic control. 1384 children under 16 years of age were
recruited between May 2009 and August 2011.
Co-enrolment into the two trials was discussed with the research
network and allowed in both protocols (available for CATCH at
www.hta.ac.uk/1867; for CHiP at www.chip-trial.org.uk). Strate-
gies for seeking consent to both trials were agreed with the chief
investigators of both trials. Due to pressure to meet the
recruitment target for CHiP it was agreed that patients eligible
for both CATCH and CHiP would be approached for CHiP
before being given any information about CATCH. In this way,
units could open for CATCH without any potential detriment to
CHiP recruitment.
Both trials recruited from elective and emergency admissions.
Timelines for eligibility, consent and randomisation for elective
and emergency patients are shown in Figure 1. For emergency
admissions eligible for CHiP, consent was sought prior to the
intervention. For emergency admissions in CATCH, children
were firstly randomised to a trial CVC to avoid any delay in
treatment and deferred consent was obtained once the patient was
stabilised, usually within 48 hours of CVC insertion. An
amendment to the Medicines for Human Use (Clinical Trials)
Regulations in 2006 (UK SI 2006 No 2984) allows patients to be
included in a trial before consent has been obtained if urgent
treatment is required, and CATCH is the first UK trial to adopt
deferred consent for children.
For elective surgical patients, consent was obtained prospec-
tively for both trials. For CATCH, children were randomised
before surgery. For CHiP, elective children did not become
eligible until admitted to PICU after surgery. In these cases,
parents would be approached for CATCH before becoming
eligible for CHiP.
Results
PICU Decisions
Five PICUs had the opportunity to recruit to both CATCH
and CHiP. Only two units decided to adopt co-enrolment for
CATCH and CHiP (Units 1 and 2 in Figure 2). These two units
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chose to co-enrol children to both trials so that recruitment for
both trials could be maximised. Three units (Units 3 to 5 in
Figure 2) decided not to allow children to be recruited into both
trials. Of these three, one unit delayed recruiting elective patients
for CATCH until CHiP had closed, resulting in a loss of six
recruiting weeks for this unit. Reasons given for deciding not to
allow co-enrolment were concerns about jeopardising recruit-
ment targets for CHIP (the trial was scheduled to close in August
2011), asking too much of parents due to the overwhelming
amounts of information to explain to parents for two trials and
the already stressful situation of having a child in need of
intensive care. One PICU had a policy against co-enrolment.
Parental Decisions
Of the two units that adopted co-enrolment, Unit 1 recorded
the number of children eligible, approached and consented to both
trials. Unit 2 did not record data on approaches or refusals, but
consented a total of 14 children to CHiP during the overlap
period, one of whom was successfully co-enrolled to CATCH.
Figure 3 shows the number of co-enrolments for emergency
patients randomised to CATCH at Unit 1. In total, 35 sets of
parents/guardians were approached for both studies (including 3
who declined consent to CHiP due to not wanting to take part in
any research and so were not actually approached for CATCH).
Two patients who had declined consent to CHiP died before being
approached for CATCH and parents are being followed-up for
deferred consent as per protocol. The consent rate was 82% (29/
35) for CATCH and 51% (18/35) for CHiP.
Recruitment rates for parents approached at the same PICU for
a single study were 78% (47/60, CATCH emergency admissions)
and 51% (192/377, CHiP), suggesting that co-enrolment did not
affect recruitment. This is supported by the reasons given for
declining consent to CATCH after having been approached for
CHiP (Table 1). These reasons were those given by parents to
research nurses when asked, and may not provide in-depth
understanding of parental decisions.
Parents of children admitted to this PICU whilst both trials were
on-going were more likely to consent to CATCH than CHiP.
Possible reasons for this difference are that emergency admissions
approached for CATCH had already been randomised to a trial
CVC - so parents were consenting to data collection only – and
that CATCH posed minimal risk to children compared with
greater risks involved with CHiP. For CHiP, consent could mean a
change in treatment plan. Secondly, consent for CHiP was sought
prior to randomisation, and the limited time to consider study
participation might have deterred some parents. This limited time
frame also meant that some eligible children were not approached
for CHiP.
Of 11 elective patients consented to CATCH, two later became
eligible for CHiP (after surgery). Neither of these children were
approached for CHiP in time and so no elective patients were co-
enrolled.
Consent Process
The research teams for both trials in Unit 1 worked together to
facilitate co-enrolment. The same team approached the parents
about both trials if they already had a rapport with the parents, so
Figure 1. Timelines for eligibility, consent and randomisation for elective and emergency admissions for CATCH and CHiP.
doi:10.1371/journal.pone.0041791.g001
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that families were not meeting too many new faces. Communi-
cation between teams was important to minimise approaches to
parents – if a parent declined to consent for CHiP due to not
wanting to take part in any kind of research, they were not
approached for CATCH.
Parents were approached for CATCH after they had made a
decision about whether or not to enrol for CHiP in all but two
situations: 1) when children became eligible for CHiP after having
been approached for CATCH, and 2) on two occasions, research
nurses felt it was appropriate to approach for both trials together
(simultaneous consent). Research nurses found it easiest to consent
separately for each trial although simultaneous consent was
successful on both occasions when this was attempted. Feedback
from research nurses indicated that some parents found the
responsibility of having to make a decision about consent to a trial
too burdensome at their time of stress, and would have preferred
that the decision was made by the medical team. This was
reflected in the high recruitment rate for emergency CATCH
patients, who would already have had the intervention when
consent was sought.
Figure 2. Period of trial overlap for PICUs recruiting to CATCH and CHiP during the same time period.
doi:10.1371/journal.pone.0041791.g002
Figure 3. Emergency recruitment to CATCH and co-enrolment with CHiP.
doi:10.1371/journal.pone.0041791.g003
Co-Enrolment in Paediatric Intensive Care
PLoS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e41791
In Unit 2, research nurses expressed that they found it difficult
to talk to parents about both trials at the same time, and the
parents of the child that did co-enrol were approached on different
days. However, research nurses at this unit felt that co-enrolment
is important and co-enrolment with CATCH and other on-going
trials is continuing.
Discussion
Most PICUs refused to co-enrol citing concerns about
jeopardising recruitment to CHiP (which was already running),
and too much information for parents. These concerns were not
supported by evidence from the PICUs that did co-enrol. Consent
rates for children approached for co-enrolment were similar to
overall consent rates, and reasons for refusal did not mention
information overload. However, parents had a clear preference for
the study that did not involve a change in treatment, concerned
interventions already in routine use, and posed minimal risk to
patients. Although based mainly on findings from one PICU, our
experience with parental decisions in CATCH and CHiP is
supported by previous small studies showing that the majority of
parents are willing to be approached for multiple trials [19,20].
The perceived ethics restrictions and concerns about recruit-
ment targets were barriers to PICU decisions to enrol children into
both trials. In the one unit that did co-enrol, the process for
consenting to two trials was determined by two main issues. First,
priority was given to CHiP recruitment so that sample size targets
could be met, which meant that deferred consent for CATCH was
delayed further whilst parents were given time to consider
participating in CHiP. Second, ethics restrictions on modification
of existing patient information leaflets, which meant that research
nurses were unable to present simple information for both trials
together thereby minimising the burden on parents.
Research evidence shows that presenting comprehensive but
concise information may increase the level of understanding and
the likelihood of true informed consent [21]. Strategies for the
whole consent process (information sheets and how to approach
patients) when more than one trial is available need to be carefully
developed, piloted and modified if necessary. Ethics approval of
combined forms of patient information also needs to be flexible
and rapid, to avoid impeding study start up or recruitment.
The decision to allow co-enrolment needs careful consideration
of the trials in question and potential impact on results, possible
interaction between therapies, internal and external validity and
safety (e.g. maximum blood volume allowed for research)
[22,23,24]. For large pragmatic trials such as CATCH, overlap
with other trials is one aspect of the heterogeneity of practice
within PICUs, whereas co-enrolment in smaller efficacy studies
may not be appropriate. As CATCH is a low-risk trial, we are not
able to make assumptions about co-enrolment for studies where
parents are asked to take more than one moderate risk.
Clinicians’ and researchers’ concerns about co-enrolment centre
mainly on the potential burden of multiple trials on parents, yet
others argue that parents have the right to be made aware of all
possible options for their child [25]. Without co-enrolment, the
priority given to trials is determined by chief investigators or
PICUs rather than patient choice. The little research that has been
conducted on parental opinions suggests that parents are
supportive of co-enrolment (in neonates), and that the possibility
of any beneficial new treatment and the general benefits of being
involved in a trial are attractive to parents [19,20]. The number of
trials offered to parents should not be overwhelming (one survey
found that parents of neonates on average thought that two trials
at a time would be acceptable) [20]. However, defining a
maximum number of trials has issues - some patients may not
be offered entry into a study if they had reached their maximum,
potentially jeopardising recruitment targets or introducing bias
into analysis [26].
Our examination of PICU and parental decisions in recruiting
to two large RCTs has highlighted the importance, acceptability
and success of recruitment into multiple studies, but also that
barriers to co-enrolment remain. Our experience with CATCH
and CHiP should encourage both ethics committees and clinicians
to feel confident about the acceptability and feasibility of co-
enrolment and to develop strategies that minimise burden on
parents but allow the capacity for important research in PICU to
continue to increase [11,12].
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